LivaNova (NASDAQ:LIVN) Reaches New 52-Week High – Still a Buy?

Posted by Stanley Muller on Jun 9th, 2026

LivaNova PLC (NASDAQ:LIVN – Get Free Report)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $77.80 and last traded at $77.1650, with a volume of 30536 shares trading hands. The stock had previously closed at $74.80.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LIVN shares. Robert W. Baird reduced their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Mizuho raised their price objective on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Finally, Needham & Company LLC raised their price objective on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.38.

Check Out Our Latest Analysis on LivaNova

LivaNova Stock Up 2.1%

The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The stock has a market capitalization of $4.20 billion, a P/E ratio of 39.06 and a beta of 0.88. The firm has a 50-day simple moving average of $67.81 and a 200 day simple moving average of $65.16.

LivaNova (NASDAQ:LIVN – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts forecast that LivaNova PLC will post 3.72 EPS for the current year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.35% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Large investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its position in shares of LivaNova by 168.1% during the third quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company’s stock worth $1,421,000 after acquiring an additional 17,007 shares during the last quarter. Allianz Asset Management GmbH bought a new position in shares of LivaNova during the third quarter worth about $7,687,000. LSV Asset Management raised its position in shares of LivaNova by 25.4% during the third quarter. LSV Asset Management now owns 674,610 shares of the company’s stock worth $35,336,000 after acquiring an additional 136,600 shares during the last quarter. Boone Capital Management LLC acquired a new stake in LivaNova during the third quarter worth approximately $8,796,000. Finally, Rock Point Advisors LLC bought a new stake in LivaNova in the third quarter worth approximately $3,066,000. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.